The present invention relates to an improved and industrially advantageous process for the preparation of (1S, 4S, 5S) -4-bromo-6-oxabicyclo [3.2.1] octan-7-one represented by the following formula (I) which is a key intermediate in the synthesis of edoxaban, a compound that exhibits an inhibitory effect on activated blood coagulation factor X (also referred to as activated factor X or FXa), and is useful as a preventive and/or therapeutic drug for thrombotic diseases. The process includes reacting (1S) -cyclohex-3-ene-1-carboxylic acid of formula (II) with a brominating agent selected from the group consisting of N-bromosuccinimide or 1, 3-dibromo-5, 5-dimethylhydantoin in the presence of a base selected from calcium oxide or calcium hydroxide in a solvent selected from the group comprising of dichloromethane, toluene, tetrahydrofuran, ethy1 acetate, hexanes, cyclopentyl methyl ether (CPME) or a mixture thereof to get ( 1S, 4S, 5S) -4-bromo-6-oxabicyclo [3.2.1] octan-7-one of formula (I).
本发明涉及一种改良的、具有工业优势的制备(1S, 4S, 5S)-4-
溴-6-氧代双环[3.2.1]辛-7-酮(
化学式(I))的方法,该化合物是合成
依度沙班的关键中间体,
依度沙班是一种对激活的血液
凝血因子X(也称为激活因子X或FXa)具有抑制作用的化合物,可用作预防和/或治疗血栓性疾病的药物。该方法包括将
化学式(II)的(1S)-环己-3-烯-1-
羧酸与从N-
溴代琥珀
酰亚胺或
1,3-二溴-5,5-二甲基海因酰
脲中选择的
溴化试剂,在选择自
氧化钙或
氢氧化钙中的一种碱和
二氯甲烷、
甲苯、
四氢呋喃、
乙酸乙酯、己烷、
环戊基甲醚(CPME)或其混合物为溶剂的条件下反应,得到
化学式(I)的(1S, 4S, 5S)-4-
溴-6-氧代双环[3.2.1]辛-7-酮。